Combination Antiretroviral Therapy (cART)

DRUG4 trials

Sponsors

Indiana University, Imperial College London, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

AtherosclerosisCardiovascular DiseasesHIVHIV InfectionsVascular Diseases

Phase 1

Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy

CompletedNCT03208231

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2018-08-06End: 2021-02-11Updated: 2023-05-24

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

CompletedNCT03497676

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2019-04-03End: 2025-04-22Updated: 2026-01-28

Phase 2

Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People

CompletedNCT00864916

Indiana UniversityAtherosclerosis, Cardiovascular Diseases, HIV +2

Start: 2009-03-31End: 2012-12-31Updated: 2014-05-12

Research In Viral Eradication of HIV Reservoirs

CompletedNCT02336074

Imperial College LondonHIV

Start: 2015-11-27End: 2023-03-31Updated: 2023-10-23

Related Papers

Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study.

2026-01-14

Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial.

2026-01-14

Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control.

2025-07-041 citations

Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.

2024-04-0119 citations

Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.

2024-04-0116 citations

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions.

2023-10-116 citations

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.

2020-02-1998 citations

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).

2019-05-0154 citations

The Mission is Remission

The Pediatric Infectious Disease Journal2018-10-222 citations

Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial.

2013-04-0919 citations